How to Help Your Patients Save Money on Otezla: A Provider's Guide to Savings Programs

Cost is one of the most common reasons patients with appropriate indications for Otezla (apremilast) either never start treatment or discontinue it prematurely. With a list price of approximately $5,000 to $6,800 per month and no US generic expected until 2028-2029, the financial barrier for uninsured and underinsured patients is substantial. However, Amgen has built a robust financial assistance infrastructure around Otezla — and knowing how to use it effectively can make the difference between a patient who gets the treatment they need and one who doesn't. This guide walks through every program and how your practice can facilitate enrollment.

The Financial Landscape: Why Otezla Costs What It Costs

Otezla is a specialty-tier medication on virtually all formularies, typically placed on Tier 4 or Tier 5. This means that even insured patients face substantial cost-sharing without manufacturer assistance. The list price of approximately $5,000 to $6,800 per 30-day supply reflects Amgen's investment in clinical development and the current absence of US generic competition, which will persist until approximately 2028-2029 following the April 2023 patent ruling.

From a practical standpoint, your patients fall into several categories that determine which savings programs apply to them: commercially insured (employer or marketplace plans), Medicare Part D, Medicaid, and uninsured. Each category has different tools available, and your practice's role in facilitating enrollment varies accordingly.

Program 1: Amgen Commercial Copay Card

For patients with commercial (private) insurance, the Amgen copay card program is the most valuable financial assistance tool available. Eligible patients pay as little as $0 per prescription fill, with Amgen covering the difference between the patient's copay and the drug cost up to program maximums.

Enrollment specifics:

Enrollment method: Via Amgen SupportPlus at otezla.com/enroll or by calling 1-833-442-6436

Patient must be physically present or on the phone to accept terms and complete patient authorization

Upon enrollment, patient receives a digital copay card immediately via email and on-screen confirmation

Eligibility: Commercially insured patients only; NOT available for Medicare, Medicaid, TRICARE, VA, or other federal programs

Annual program maximums apply — check current terms at otezla.com/enroll

Prescriber tip: Accumulator adjustment programs (also called accumulators or maximizers) are used by some employer and PBM plans to prevent manufacturer copay cards from counting toward the patient's deductible and out-of-pocket maximum. If your patient's plan has this feature, the manufacturer copay benefit may be exhausted before the patient meets their deductible — creating a cost gap mid-year. Ask your patient to check with their pharmacy benefits manager if this is a concern.

Program 2: Bridge to Commercial Coverage

The Bridge to Commercial Coverage program addresses one of the most common and frustrating access problems: the delay between prescription and PA approval. Commercially insured patients who experience a PA delay receive free Otezla for up to 12 prescription fills (within 12 months from the first bridged fill) while their insurance approval is pending or under appeal.

Key program features:

Enrollment is automatic through Amgen SupportPlus when a PA delay or denial is identified

Ongoing eligibility (after first 3 fills) requires that a PA or medical exception was denied within 90 days of first use

Once insurance approves Otezla, the bridge program ends automatically

This is a one-time offer; patients cannot re-enroll

Clinical value: Patients can start the 5-day titration and initiation phase immediately, without waiting weeks for PA resolution. This reduces treatment gaps, maintains patient confidence in the treatment plan, and allows you to assess initial tolerability during the PA review period — providing useful clinical data to support an appeal if needed.

Program 3: Amgen Safety Net Foundation

For uninsured or underinsured patients who do not qualify for the commercial copay program, the Amgen Safety Net Foundation provides free medication to qualifying individuals. Eligibility is based on income relative to the federal poverty level, insurance status, and residency.

Your practice's role: Completing the physician attestation section of the patient application is required. Encourage your office staff to be proactive about completing this documentation when patients identify as uninsured or report financial hardship. Patients can apply at amgensafetynetfoundation.com or your staff can assist. Processing typically takes 2 to 4 weeks.

Medicare Patients: What Changed in 2025-2026

Medicare patients represent a unique challenge because the commercial copay card is not available to them. However, two significant policy changes affect Medicare patients on Otezla in 2025-2026:

IRA $2,000 OOP cap (effective 2025): The Inflation Reduction Act limits annual Medicare Part D out-of-pocket drug spending to $2,000. For patients taking a specialty drug like Otezla, this cap is clinically meaningful — the drug cost effectively hits the cap within the first few months of the year, after which the plan covers 100%.

Extra Help / Low-Income Subsidy: Medicare beneficiaries with limited income and resources may qualify for the Extra Help program, which significantly reduces premium, deductible, and copay costs for Part D covered drugs. Refer these patients to SSA (1-800-772-1213) or medicare.gov to check eligibility.

Otezla insurance specialists: Call 844-468-3952 for Medicare-specific insurance questions about Otezla coverage.

Formulary Optimization: Otezla vs. Otezla XR

A practical tip often overlooked: Otezla (30 mg BID) and Otezla XR (75 mg QD) may have different formulary placements on some insurance plans — meaning one formulation may carry a lower copay tier than the other. Before writing the prescription, it's worth asking your patient to check with their insurance plan or pharmacy benefits manager about which formulation has more favorable cost-sharing. Patients can switch between formulations; patients taking 30 mg BID can switch to 75 mg XR the day after their last 30 mg dose.

Creating a Practice Workflow for Otezla Access

The most effective way to ensure your patients access Otezla is to build a systematic practice workflow that initiates all support programs simultaneously at the point of prescribing. A recommended workflow:

At the visit: Write prescription, route to appropriate specialty pharmacy, verify patient insurance type

Same day: Submit PA request with complete documentation (diagnosis, severity, prior therapies, rationale)

Patient enrollment: Direct commercially insured patients to enroll in Amgen SupportPlus (1-833-442-6436 or otezla.com/enroll); assist uninsured patients with Safety Net Foundation application

Bridge program: Ensure patient is enrolled if PA is pending; patient can start treatment immediately

Follow-up: Confirm with staff that prescription has been received and processed by specialty pharmacy within 3-5 business days of submission

medfinder as a Patient Resource

Even after savings programs are enrolled and PA is obtained, some patients still face logistical challenges in finding which specialty pharmacy can fill their prescription promptly. medfinder is a service that contacts pharmacies on patients' behalf to find which ones can fill a specific prescription, providing results via text message. Recommending medfinder as a resource for your patients can reduce the administrative burden on your office. For a comprehensive overview of current Otezla access challenges, also see What Providers and Prescribers Need to Know About Otezla Access in 2026.